Trial Profile
Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- Acronyms AxitinibACC
- 01 Dec 2023 Results assessing the predictive value of artificial intelligence (AI)-powered tumor-infiltrating lymphocyte (TIL) analysis in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) treated with axitinib published in the Head and Neck
- 27 Jul 2021 Results published in the Clinical Cancer Research.
- 31 May 2020 Primary endpoint has been met. (Progression-free survival (PFS) rate)